Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL255550 | 0.83 | ALDH1A1 (0.50) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL519679 | 0.82 | SIRT6 (0.43) | MEN1KMT2AMMP2ALDH1A1MAPT | |
| SCHEMBL23728185 | 0.73 | SMN1; SMN2 (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL16530352 | 0.70 | ALDH1A1 (0.42) | MEN1KMT2AL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28539303 | 0.70 | RIPK1 (0.47) | KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL20908728 | 0.70 | HRH3 (0.46) | MEN1KMT2AALDH1A1MAPTSIRT6 | |
| SCHEMBL1581647 | 0.69 | SLC18A3 (0.48) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL28545615 | 0.68 | ALDH1A1 (0.42) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL25295389 | 0.68 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1MAPTMAPK1 | |
| SCHEMBL16570024 | 0.67 | HSD11B1 (0.55) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249123-B2 | Pyridinones/pyrazinones, method of making, and method of use thereof | GENENTECH, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2611790-B1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20130281432-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GENENTECH, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| EP-2611790-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | Gilead Connecticut, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012031004-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281432-A1 | PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, PDXK, TYK2 | MEN1 2702/4885KMT2A 3969/4885L3MBTL1 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.